Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Male or female with a body weight ≥10 to 40 kg~* Patients suffering from acute uncomplicated Plasmodium falciparum malaria~* Malaria diagnosis confirmed by a positive blood smear with asexual forms of Plasmodium falciparum (i.e., identification of asexual parasite count ≥1,000 to 250,000 per mm3)~* Ear temperature 37.5°C or a history of fever within the last 48 hours~* Haemoglobin 7g/100ml~* Written informed consent and written consent from parents/guardian for children below age of consent (verbal consent in presence of literate witness is required for illiterate patients or parents/guardians).~Exclusion Criteria:~Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment (defined according to WHO Recommendations Malaria Control Today, RBM Working Document, March 2005, see Appendix 2)~* Patients with known hypersensitivity or allergy to artemisinin derivatives or mefloquine or mefloquine chemically related compounds (for example quinine and quinidine)~* Patients who had received quinine or any artemisinin derivatives within 12 hours prior to study start~* Patients who had received any other adequate antimalarial drug therapy including antibiotics which might be active against malaria infection within 1 week prior to study start~* Patients who had received investigational (unlicensed) drugs as well as mefloquine within 30 days prior to study start~* Patients with known history of psychiatric disorders~* Patients with known history of cardiac diseases and arrhythmia~* Patients with known sickle cell disease~* Patients with clinical signs of or laboratory evidence for any other severe hepatic, renal, pulmonary, cardiac, metabolic, psychiatric, cancer or haematologic diseases~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).